Giulia Marchetti

Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment.

Delayed-type hypersensitivity skin testing can predict CD4 count increase in HIV patients with poor immunologic response to HAART.

Interleukin-2 immunotherapy exerts a differential effect on CD4 and CD8 T cell dynamics.

IL-7/IL-7 receptor system regulation following IL-2 immunotherapy in HIV-infected patients.

Immunomodulation induced by tucaresol in HIV infection: results of a 16 week pilot Phase I/II trial.

Partial immune reconstitution following highly active antiretroviral therapy: can adjuvant interleukin-2 fill the gap?

Comparison between spoligotyping and IS6110 restriction fragment length polymorphisms in molecular genotyping analysis of Mycobacterium tuberculosis strains.

Spoligotyping and Mycobacterium tuberculosis.

Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART.

Early impairment of gut function and gut flora supporting a role for alteration of gastrointestinal mucosa in human immunodeficiency virus pathogenesis.

Untangling the immunological implications of nadir on CD4+ cell recovery during suppressive highly active antiretroviral therapy.

Effective nocturnal oxygen therapy increases circulating level of tumor necrosis factor-alpha in heart failure.

The challenge of IL-2 immunotherapy in HIV disease: "no through road" or turning point?

Serum alpha-fetoprotein levels predict early virologic response in HIV-positive subjects treated for chronic hepatitis C.

Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy.

Successful rescue therapy with a darunavir/ritonavir and etravirine antiretroviral regimen in a child with vertically acquired multidrug-resistant HIV-1.

Rhodococcus equi infection in a patient with spinocellular carcinoma of unknown origin.

Fully immunocompetent CD8+ T lymphocytes are present in autologous haematopoietic stem cell transplantation recipients despite an ineffectual T-helper response.

Abacavir and cardiovascular risk in HIV-infected patients: does T lymphocyte hyperactivation exert a pathogenic role?

Sudden cardiac death in a young HIV-positive man on effective antiretroviral therapy.

The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options.

Early initiation of highly active antiretroviral therapy fails to reverse immunovirological abnormalities in gut-associated lymphoid tissue induced by acute HIV infection.

CD8+ hyperactivation and senescence correlate with early carotid intima-media thickness in HIV+ patients with no cardiovascular disease.

CD4+ T cell depletion, immune activation and increased production of regulatory T cells in the thymus of HIV-infected individuals.

Skewed T-cell maturation and function in HIV-infected patients failing CD4+ recovery upon long-term virologically suppressive HAART.

Reduced CD127 expression on peripheral CD4+ T cells impairs immunological recovery in course of suppressive highly active antiretroviral therapy.

Noncirrhotic portal hypertension in HIV-infected patients: a case control evaluation and review of the literature.

Qualitative immune modulation by interleukin-2 (IL-2) adjuvant therapy in immunological non responder HIV-infected patients.

Increased bone marrow interleukin-7 (IL-7)/IL-7R levels but reduced IL-7 responsiveness in HIV-positive patients lacking CD4+ gain on antiviral therapy.

Detrimental effect of atazanavir plasma concentrations on total serum bilirubin levels in the presence of UGT1A1 polymorphisms.

Evidence for polymicrobic flora translocating in peripheral blood of HIV-infected patients with poor immune response to antiretroviral therapy.

Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count.

Reduced Central Memory CD4+ T Cells and Increased T-Cell Activation Characterise Treatment-Naive Patients Newly Diagnosed at Late Stage of HIV Infection.

HIV-Infected Late Presenter Patients.